Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Aihua Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8803-4595; OpenAlex author ID A5075219319. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2016: 1 paper · 2017: 4 papers · 2018: 2 papers · 2019: 4 papers · 2020: 4 papers · 2021: 2 papers · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: 3 papers

Papers 26

  1. Correction to: Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling. Last author DOI 10.1038/s41416-025-03208-w↗
  2. [Corrigendum] Furin promotes epithelial‑mesenchymal transition in pancreatic cancer cells via Hippo‑YAP pathway. Co-author DOI 10.3892/ijo.2025.5797↗
  3. SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. Co-author DOI 10.7150/jca.114356↗
  4. LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway. Co-author DOI 10.1016/j.abb.2023.109783↗
  5. LncRNA FAM83A-AS1 promotes epithelial-mesenchymal transition of pancreatic cancer cells via Hippo pathway. Co-author DOI 10.1080/15384101.2023.2216507↗
  6. Hypoxia-elicited Exosomes Promote the Chemoresistance of Pancreatic Cancer Cells by Transferring LncROR via Hippo Signaling. Co-author DOI 10.7150/jca.81320↗
  7. Activated Stellate Cell Paracrine HGF Exacerbated Pancreatic Cancer Cell Ferroptosis Resistance. Co-author DOI 10.1155/2022/2985249↗
  8. Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. Co-author DOI 10.1155/2022/5361241↗
  9. O-GlcNAcylation of ZEB1 facilitated mesenchymal pancreatic cancer cell ferroptosis. Co-author DOI 10.7150/ijbs.71520↗
  10. The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. Co-author DOI 10.1002/1878-0261.12836↗
  11. Stearoyl-CoA Desaturase 1 Potentiates Hypoxic plus Nutrient-Deprived Pancreatic Cancer Cell Ferroptosis Resistance. Co-author DOI 10.1155/2021/6629804↗
  12. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.29308↗
  13. Methyl-CpG-binding domain 3 inhibits stemness of pancreatic cancer cells via Hippo signaling. Co-author DOI 10.1016/j.yexcr.2020.112091↗
  14. Methyl-CpG-binding protein 2 drives the Furin/TGF-β1/Smad axis to promote epithelial-mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1038/s41389-020-00258-y↗
  15. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14894↗
  16. Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness. Co-author DOI 10.1038/s41419-019-1956-8↗
  17. Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells. Co-author DOI 10.2147/dddt.s199459↗
  18. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. Co-author DOI 10.7150/jca.32052↗
  19. The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Co-author PMID 30949406↗
  20. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway. Co-author DOI 10.1016/j.bbadis.2018.03.005↗
  21. Long non‑coding RNA PVT1 promotes epithelial‑mesenchymal transition via the TGF‑β/Smad pathway in pancreatic cancer cells. Co-author DOI 10.3892/or.2018.6462↗
  22. Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling. Last author DOI 10.1038/bjc.2016.397↗
  23. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Co-author DOI 10.1080/15384101.2017.1380125↗
  24. The mir-675-5p regulates the progression and development of pancreatic cancer via the UBQLN1-ZEB1-mir200 axis. Co-author DOI 10.18632/oncotarget.15330↗
  25. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway. Co-author DOI 10.3892/ijo.2017.3896↗
  26. MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.7507↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Xu · 19 shared papers, 2016–2025 · strength 2.21
  2. Wan‐Xin Peng · 9 shared papers, 2016–2025 · strength 1.00
  3. Youli Zhang · 10 shared papers, 2016–2025 · strength 0.99
  4. Huizhi Wang · 6 shared papers, 2019–2023 · strength 0.81
  5. Haitao Zhu · 5 shared papers, 2019–2022 · strength 0.61
  6. Zhengyang Zhang · 3 shared papers, 2019–2025 · strength 0.51
  7. Huizhi Wang · 3 shared papers, 2020–2023 · strength 0.42
  8. Yuntao Ding · 2 shared papers, 2023 · strength 0.41
  9. Yanfang Liu · 3 shared papers, 2019–2022 · strength 0.36
  10. Yawen Liu · 2 shared papers, 2021–2022 · strength 0.28
  11. Dongqing Wang · 1 shared paper, 2025 · strength 0.28
  12. Dongqing Wang · 2 shared papers, 2021–2022 · strength 0.28
  13. Yawen Liu · 3 shared papers, 2019–2020 · strength 0.28
  14. Lu Ge · 3 shared papers, 2016–2020 · strength 0.24
  15. Jingyu Min · 2 shared papers, 2020–2021 · strength 0.22
  16. Qi Wang · 1 shared paper, 2023 · strength 0.20
  17. Wei Chen · 2 shared papers, 2020 · strength 0.20
  18. Min Xu · 1 shared paper, 2023 · strength 0.19
  19. Meiting Zhang · 2 shared papers, 2018–2019 · strength 0.17
  20. Qiwei Wu · 1 shared paper, 2022 · strength 0.15
  21. Xin Wang · 1 shared paper, 2022 · strength 0.15
  22. Mengqi Liu · 1 shared paper, 2022 · strength 0.15
  23. Jie Gao · 1 shared paper, 2021 · strength 0.13
  24. Kang Wang · 1 shared paper, 2019 · strength 0.10
  25. Lirong Zhang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.